Progenics Pharmaceuticals News
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) (Nasdaq:^NBI) effective prior to market open on Monday, May ...
Salix continues to guide towards earnings of $3.37 per share on product revenues of $920 million in 2013.
Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of DirectorsBusiness Wire May 10
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. today announced its results of operations for the quarter ended March 31.